

CYPROTEX LAUNCHES “E-STORE” FOR ONLINE ORDERING OF ADME-TOX SERVICES

▶ E-STORE SIMPLIFIES ACCESS TO CYPROTEX’ LEADING ADME-TOX SERVICES WITH IMPROVED EFFICIENCY AND REDUCED LEAD TIME

Hamburg, Germany, 10 October 2023:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the official launch of the Cyprotex “[e-Store](#)”, offering simplified online access to the company’s comprehensive range of ADME-Tox services.

The e-Store, Cyprotex’ new e-commerce platform, streamlines and accelerates the buying process for its users. The efficient platform enables registered users to evaluate and order Cyprotex’ offering around the clock, seven days a week. It provides instant access to prices and detailed protocols online. Users can easily place orders, track them, and reorder when needed. This enables the lead time for services to be reduced as the study can be scheduled without delay. The e-Store offers a range of different payment options including credit card, existing purchase order or invoice. Educational content, and special promotions are also instantly accessible on the platform.

Dr Matthias Evers, Chief Business Officer of Evotec SE, commented:

“Profiling for ADME-Tox is a vital part of the drug discovery and development process and plays an important role in de-risking a project. The new e-Store streamlines access to Cyprotex’ market leading ADME-Tox services providing an efficient way to order online. This reduces both the administrative burden and the lead time for the study enabling users of the platform to receive their data quicker.”

Visit the Cyprotex e-Store at: <https://cyprotex-store.evotec.com>

ABOUT CYPROTEX

Established in 1999, Cyprotex Limited was acquired by Evotec (www.evotec.com) in 2016. Cyprotex, an Evotec company, has sites at Alderley Park near Macclesfield, UK and in Framingham near Boston, USA. The company has dedicated and highly qualified employees with proven experience in a wide range of specialist techniques acquired across diverse industries. The majority of our clients focus in pharmaceutical research, however, we also support clients in the chemical, cosmetics and personal care, agrichemical and tobacco industries. Cyprotex specialises in in vitro and in silico ADME-Tox services.

For further information, please contact the Corporate Communications Team:

Hinnerk Rohwedder, Director of Global Corporate Communications, hinnerk.rohwedder@evotec.com;

Gabriele Hansen, SVP Head of Global Corporate Communications, gabriele.hansen@evotec.eu, www.evotec.com

This includes in vitro ADME screening to support discovery projects, regulatory in vitro ADME and DDI studies during pre-clinical and clinical development, specialist mechanistic in vitro human and animal toxicity models (e.g. 3D models and MEA electrophysiology) and PBPK/QSAR modelling expertise. Further information on Cyprotex is available on our website at www.cyprotex.com.

ABOUT EVOTEC SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter [@Evotec](https://twitter.com/Evotec) and [LinkedIn](https://www.linkedin.com/company/evotec).

FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.